A bill for an act relating to self-administered hormonal contraceptives.
HSB695 would create a new Iowa law allowing pharmacists to dispense self-administered hormonal contraceptives to adults age 18 and older under a standing order issued by the medical director of the Department of Health and Human Services. The bill defines these contraceptives to include FDA-approved oral hormonal contraceptives, vaginal rings, and patches used to prevent pregnancy, while expressly excluding drugs intended to induce abortion. Initial dispensing would be limited to a three-month supply, with later refills allowed up to a twelve-month supply at one time.
The bill sets detailed conditions for pharmacist participation. Pharmacists would have to complete approved training and continuing education, verify patient identity and age, obtain a self-screening risk assessment, and take blood pressure readings before dispensing. They would also have to provide written information and counseling on proper use, side effects, backup contraception, emergency care, STI risk, and the importance of seeing a primary care or women’s health provider. The bill also limits dispensing if the risk assessment indicates it is unsafe, if the patient has not seen a practitioner within 27 months, or if the pharmacist requires an appointment as a condition of dispensing.
HSB695 also amends Iowa’s prescription contraceptive coverage law to require health insurance policies, contracts, and plans that cover outpatient prescription drugs or services to specifically cover self-administered hormonal contraceptives dispensed by prescription or standing order, beginning with policies issued or renewed on or after January 1, 2027. It extends these coverage requirements to group and individual plans, including public employee plans, while preserving standard cost-sharing rules and excluding certain limited coverage types such as Medicare supplement and short-term coverage. The bill further directs the Board of Pharmacy, Board of Medicine, and HHS to expand the state’s drug prescribing and dispensing information program to track pharmacist dispensing of these contraceptives, and it applies the measure to Medicaid unless federal law would prevent it.
The overall sentiment reflected in the bill text is strongly supportive of expanding access to contraception through pharmacies, while also emphasizing safety, oversight, and patient counseling. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate or formal opposition in the available materials. The structure of the bill suggests a policy goal of increasing convenience and access while maintaining medical safeguards and regulatory control.
The main points of potential contention are likely to be the scope of pharmacist authority, the insurance coverage mandate, and the bill’s treatment of reproductive health policy. Some stakeholders may focus on whether pharmacist dispensing should be limited to adults and tied to a standing order, while others may question the required training, reporting, and blood pressure screening requirements. The explicit exclusion of abortion-inducing drugs and the requirement that patients receive counseling about alternative contraceptive methods and primary care follow-up may also be significant issues for both supporters and critics.
The bill would add a new section to Iowa Code chapter 155A authorizing pharmacist dispensing of self-administered hormonal contraceptives under a statewide standing order and would amend Iowa’s contraceptive insurance coverage statute, section 514C.19, to require coverage of those products and related dispensing beginning January 1, 2027. It would also expand state reporting requirements through the pharmacy information program, and it would apply to Medicaid subject to federal funding and compliance limits. The measure would affect pharmacists, the Department of Health and Human Services, the Board of Pharmacy, the Board of Medicine, insurers, Medicaid managed care organizations, and adult patients seeking contraceptives.
Based on the bill text alone, the measure appears generally favorable toward expanding contraceptive access and reducing barriers to obtaining birth control, especially by allowing pharmacy-based dispensing without a separate prescription order. The bill also reflects a cautious, regulated approach by requiring training, screening, counseling, and referral procedures. No committee discussion or vote history was provided, so there is no recorded public sentiment beyond the policy design itself.
Likely areas of contention include whether pharmacists should be allowed to dispense hormonal contraceptives under a standing order, whether the insurance mandate should apply broadly to health plans, and whether the reporting and screening requirements are sufficient or overly burdensome. The exclusion of abortion-inducing drugs may be important to opponents or supporters depending on their views on reproductive health policy. Another possible point of dispute is the balance between access and oversight, including the 18-and-over limit, the 27-month practitioner-visit requirement, and the liability immunity granted to pharmacists and the medical director.